Search

Search Constraints

You searched for: Author/Creator Bartlett, N.

Search Results

1. A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. (June 2017)

3. IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. (June 2017)

4. OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS. (June 2017)

5. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL. (June 2017)

6. POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017)

7. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL. (12th June 2019)

8. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022)